Literature DB >> 9878522

Independent feeding and metabolic actions of orexins in mice.

M Lubkin1, A Stricker-Krongrad.   

Abstract

Orexin-A and orexin-B (OX peptides) are two putative products of a newly discovered secreted protein encoded by a mRNA restricted to neuronal cell bodies of the lateral hypothalamus (LH). Because the activation of the LH can induce changes in energy balance, we wanted to investigate the actions of OX peptides on energy metabolism in mice. We injected male C57BL/6J mice with different doses (1, 3, and 10 nmol) of orexin-A and orexin-B into the third ventricle (i3vt). A single i3vt injection of orexin-A 3 h into the light period slightly stimulated feeding at the lowest dose only over the following 4 h (11 +/- 09 mg/mouse vs 80 +/- 13 mg/mouse, p < 0.05). Orexin-B showed no effects at any dose. We therefore investigated the effects of 3 nmol orexin-A on energy utilization using indirect calorimetry. Single i3vt injection 3 h after light on, or just before dark onset, or in 4-h fasted mice resulted in increases in the metabolic rate. These effects were associated with decreases or increases in the respiratory quotient regarding the time of injection or the underlying metabolic state of the mice. The present findings provide direct evidence that OX peptides are more likely to be involved in the control of energy metabolism than of food intake in mice. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9878522     DOI: 10.1006/bbrc.1998.9750

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  62 in total

Review 1.  Sleep and obesity: a focus on animal models.

Authors:  Vijayakumar Mavanji; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Neurosci Biobehav Rev       Date:  2012-01-16       Impact factor: 8.989

2.  Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins.

Authors:  H Schwimmer; H M Stauss; F Abboud; S Nishino; E Mignot; J M Zeitzer
Journal:  J Appl Physiol (1985)       Date:  2010-08-12

Review 3.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

4.  Intracisternal injection of orexin-A prevents ethanol-induced gastric mucosal damage in rats.

Authors:  Hiroto Yamada; Satoshi Tanno; Kaoru Takakusaki; Toshikatsu Okumura
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

Review 5.  Addiction and arousal: the hypocretin connection.

Authors:  Benjamin Boutrel; Luis de Lecea
Journal:  Physiol Behav       Date:  2007-11-22

Review 6.  Role of orexin in central regulation of gastrointestinal functions.

Authors:  Toshikatsu Okumura; Kaoru Takakusaki
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

7.  Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.

Authors:  Vijayakumar Mavanji; Claudio E Perez-Leighton; Catherine M Kotz; Charles J Billington; Sairam Parthasarathy; Christopher M Sinton; Jennifer A Teske
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

8.  Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.

Authors:  Michihiro Mieda; Jon T Willie; Junko Hara; Christopher M Sinton; Takeshi Sakurai; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-16       Impact factor: 11.205

9.  Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus.

Authors:  Yan Rao; Min Lu; Fei Ge; Donald J Marsh; Su Qian; Alex Hanxiang Wang; Marina R Picciotto; Xiao-Bing Gao
Journal:  J Neurosci       Date:  2008-09-10       Impact factor: 6.167

10.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.